FDA
-
-
-
-
-
-
-
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on XOMA, Ltd. (XOMA)
-
-
-
-
-
-
-
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
-
-
-
-
-
-
-
XOMA (XOMA) Earns $5M Milestone
-
-
-
-
-
-
-
XOMA Announces Evolution of Company Leadership and Succession Planning
-
-
-
-
-
-
-
XOMA (XOMA) Acquires Kuros Biosciences' Royalty Interest in Checkmate’s Vidutolimod
-
-
-
-
-
-
-
Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

